Five science start-ups have been awarded £10k, access to the Babraham Research Campus bio-incubator facilities, Accelerate@Babraham, and an extended programme of mentoring and support
Babraham 21st May 2019: Eight finalists; life science ventures covering the fields of new therapeutics, diagnostics, medical devices and manufacturing pitched head-to-head to a distinguished judging panel and an invited audience on Wednesday, May 15th, for the chance to join the Babraham Research Campus community as part of the 5-month 2019 Accelerate@Babraham programme.
The final followed on from the Babraham…
TTP enables development of MosaiQ™ diagnostic platform for transfusion typing and disease screening
Cambridge, UK, 20 May 2019: TTP plc (TTP), a leading independent technology and product development company, has announced today that it has partnered with Quotient Ltd (NASDAQ:QTNT), a commercial-stage diagnostics company committed to transforming transfusion diagnostics and beyond – to develop and implement a state-of-the-art manufacturing facility for Quotient’s proprietary MosaiQ™ system.
MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully…
Cambridge, UK, 20 May 2019: Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine today announces a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and a global leader in pulmonary arterial hypertension (PAH), to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes. This development program will be solely funded by Actelion.
Pulmonary hypertension (PH) is a progressive…
Mogrify appoints 15 new staff including, Dr Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer
Cambridge, UK, 20th May 2019: Mogrify Ltd (Mogrify), a UK company aiming to transform the future development of cell therapies, today announced that it has moved to the Bio-Innovation Centre at the Cambridge Science Park, following the appointment of 15 new staff to its scientific and management teams including, Dr. Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer. These new hires and facilities will aid Mogrify in building a scalable…
20 May 2019, Cambridge, UK: STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, today announced that it has raised an additional£14 million bringing the total Series A financing to £30 million.
The financing includes funding from new investor, Seroba Life Sciences (“Seroba”). STORM’s existing investors, Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures and IP Group also participated in the fundraise.
This extension follows the company’s rapid progress to date. It will enable STORM to advance its broad…
Boyds, the leading consultancy business that supports the development of pharmaceutical and biotech products for patient benefit, has reported record-breaking growth in its overseas turnover in the 12-months since it was recognised with one of the UK’s most prestigious awards, The Queen’s Awards for Enterprise.
Since receiving the Queen’s Award for Enterprise, International Trade for Outstanding Short-Term Growth in overseas in April 2018, Boyds, which has its headquarters in Crewe, has also grown its team with four senior appointments and opened new offices in Dublin and at Alderley Park.…
Synpromics Ltd, the leader in gene control, and Lonza Pharma & Biotech announce a partnership for the commercialisation of a number of inducible promoters to improve the manufacturing of biopharmaceuticals. The commercial agreement with Lonza follows the award of an Innovate UK grant to Synpromics announced on 23 April 2018. Lonza and Synpromics worked together to develop and test these innovative promoters in Lonza’s industry-leading GS Xceed® Expression System.
The inducible promoters will be used by Lonza to enable efficient production of several types of biological drug and is part…
14 May 2019: Norwich Plant Bioscience Ltd (PBL) and Leaf Expression Systems Ltd (Leaf) are delighted to announce a further development in their relationship, with PBL granting Leaf the exclusive rights to sub-license the Hypertrans® transient expression system, the core technology underpinning Leaf’s biologics and vaccines contract development and manufacturing services business. Apart from rights previously granted to PBL’s pre-existing licensees, this effectively transfers to Leaf full control of the Hypertrans® technology and associated patented intellectual property. This extension of…
Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical and healthcare sectors, has introduced a cell based bioassay service to meet rising demand for potency assessments.
Cell based bioassays are the primary tool for determining the biological activity of molecules, making the potency tests a critical part of drug product and drug substance quality control, product release and stability testing. Biopharma companies need to generate this information to have confidence in their drugs and comply with…
In support of its continuing growth plans, Boyds, the leading consultancy business that supports the development of pharmaceutical and biotech products for patient benefit, has appointed a new CMC regulatory affairs professional.
Claire Scruton joins Boyds as Senior Manager of CMC Regulatory Affairs and will be based at the organisation’s Cambridge office.
At Boyds, Claire will provide strategic regulatory CMC advice and operational support across a range of therapeutic areas and development stages for ATMPs, biologics and new chemical entities.
A CMC regulatory affairs professional, Claire…